OncAlert ®
The OncAlert Oral Cancer product line is comprised of proprietary tests that detect CD44 and total protein. These tests are optimized for easy use by collecting samples via an oral saline rinse. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer. Healthcare providers can get a simple and accurate assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. OncAlert RAPID test provides a qualitative result at the point of care, reporting either normal or elevated levels of oral cancer biomarkers. The test are technologically advanced and highly accurate methods to aid in the early detection of oral cancer including oral and oropharyngeal cancer.
AT RISK FOR ORAL CANCER?
Smoking tobacco
5x-9x increased risk
Smokeless tobacco
75% of daily users develop lesions
Alcohol use
9x-30x increased risk
Sexual activity
>50% of oral cancers are related to human papillomavirus (HPV)
Source: Oral Cancer Foundation
HOW IT WORKS: RESULTS IN 3 EASY STEPS
SWISH
Patient swishes and gargles a sterile saline solution in mouth for 10 seconds.
SPIT
Sample is then collected in the specimen cup.
SET
Test cassette is inserted into the specimen cup. Results should be read at 10 minutes.
CONTACT US TODAY
Get in contact with our sales contact Jacob if you have any questions.
- Email: jacob.jager@biotech-igg.com
- Phone: +46 704 533 007
Vigilant Biosciences ®
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Our point-of-care and lab-based solutions are simple, accurate and cost-effective, empowering healthcare practitioners to improve potential outcomes through earlier intervention. The Vigilant Biosciences Scientific Advisory Board comprises of distinguished thought leaders and clinical advocates across fields of head and neck surgery, oncology, and oral medicine united in improving early detection and intervention for better outcomes.
Vigilant Biosciences products are based on advanced patented technology, including an innovative methodology for measuring total protein levels and assessing the level of tumor-initiating and stem cell-associated biomarker CD44 that, together with other clinical factors, can aid clinicians in the early detection and intervention of oral cancer. These clinically validated tests enable early and accurate detection of oral cancer, potentially even before visual or physical indicators. This foundational science leverages nearly two decades of clinical research conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
